Table 3.
Patient demographics.
| Standard dosingn= 20 Mean (S.D.) | Model-based dosingn= 18 Mean (S.D.) | |
| Age (years) | 70.5 (13.3) | 68.8 (11.3) |
| Height (cm) | 167 (8.9) | 168 (10.0) |
| Weight (kg) | 91 (30.4) | 96 (32.0) |
| Body surface area (m2) | 2.0 (0.3) | 2.0 (0.3) |
| n(%) | n(%) | |
| Gender | ||
| Male | 9 (45%) | 8 (44%) |
| Female | 11 (55%) | 10 (56%) |
| Diabetes | ||
| Yes | 6 (30%) | 5 (28%) |
| No | 14 (70%) | 13 (72%) |
| Current smoker | ||
| Yes | 3 (15%) | 3 (17%) |
| No | 17 (85%) | 15 (83%) |
| Concomitant CYP2C9 medications | ||
| Inducer | 0 | 0 |
| Inhibitor | 7 (35%) | 6 (33%) |
| Substrate | 10 (50%) | 12 (67%) |
| Treatment indication | ||
| Atrial fibrillation/flutter | 9 (45%) | 3 (17%) |
| Prosthetic valve | 4 (20%) | 4 (22%) |
| Prosthetic joint | 3 (15%) | 3 (17%) |
| Deep venous thrombosis/pulmonary embolism | 3 (15%) | 6 (33%) |
| Other | 1 (5%) | 2 (11%) |